If the proposed $69-billion purchase of health insurer Aetna by CVS -- a pharmacy chain that is also a pharmacy benefit manager (PBM) -- is approved, it may be good news for the companies involved, but its potential effects on patients and providers are not so clear, experts say.
From basics like toilet paper to luxuries such as flatscreen TVs, Amazon can deliver just about anything to a doorstep these days—so, what about prescription drugs? That’s the question the company seems to be currently asking itself and is expected to announce its answer soon.
Recent rumors that Amazon is considering entering the prescription drug business have that multi-billion-dollar industry quaking in its collective boots. And for good reason: Amazon has a reputation for exposing and driving down prices for the good of consumers.
The rumored $66 billion merger of retail pharmacy CVS and health insurer Aetna holds strong potential to inflict financial pain on American patients by artificially inflating prescription drug prices while reducing transparency and competition.
Health insurance giant Anthem Inc. moved to sever ties with pharmacy-benefits manager Express Scripts Holding Co. on Wednesday, opting instead to build its own such business in collaboration with CVS Health Corp. as it looks to contain its spiraling drug costs.
Quick quiz: Where is the cheapest gas in your neighborhood? Like most Americans, I can easily come up with an answer – it’s an independently owned station about a mile away where the price drops 10 cents a gallon after 9 p.m.
When two pharmacy benefits managers (PBMs)—Express Scripts and CVS Health—recently launched direct-to-consumer, drug discount cards, the pharmacy industry might have wondered if these pharmacy middlemen were trying out a new role.
The prior authorization process is a frequent, time-consuming process for physicians. A survey of 1,000 physicians revealed they made prior authorization requests 37 times per week on average, according to data from the American Medical Association.
SAN DIEGO—July 25, 2017—InteliSyS Health™, pioneer of the first real-time prescription transparency platform, announced today that is has been selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition 2017, an awards program from the publisher of FierceHealthcare. InteliSys Health was recognized as a finalist in the category of Clinical Information Management.
Despite the healthcare ecosystem’s push for transparency, there remains a shroud of secrecy around one ubiquitous healthcare treatment tool: prescription drugs. No one — not doctors, not insurers and certainly not patients — know what they really cost.
SAN DIEGO—July 11, 2017—InteliSyS Health™, pioneer of the first real-time prescription transparency platform, announced that former Allscripts Chief Technology Officer and Chief Innovation Officer Stanley Crane has joined the executive team as CTO. Crane will guide development of InteliSys’ breakthrough point-of-care drug pricing and medication adherence tools, as well as spearhead new products in additional markets.
The Institute for Clinical and Economic Review (ICER) will work with the Department of Veterans Affairs (VA) Pharmacy Benefits Management Services office (PBM) to facilitate their integration of ICER reports into VA’s formulary management process of evaluating the comparative clinical effectiveness and value of drugs.
June 20, 2017. InteliScript, pioneer of the first real-time prescription transparency platform, today announced that it has changed its name to InteliSys Health™. The change reflects the company's strategic expansion beyond prescribing-focused solutions to a cloud-based platform.
April 26, 2017. Pharmacy benefit managers’ business practices are so opaque that employers and insurers who hire them can’t know whether the powerful middlemen are saving them money or driving up costs.